Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immunotherapy has revolutionized the diagnosis and treatment model for patients with advanced non-small cell lung cancer (NSCLC). Numerous clinical trials and real-world reports have confirmed that PD-L1 status is a key factor for the successful use of immunotherapy in NSCLC, by predicting clinical outcomes and identifying patients most likely to benefit from this treatment. Therefore, accurate and standardized evaluation of PD-L1 expression is crucial. Currently, PD-L1 testing in China faces several challenges, including a heavy pathologist workload, a shortage of highly trained pathologists plus the inadequate capacity of diagnostic laboratories, confusion around different scoring methods, cut-off values, and indications, and limited concordance between PD-L1 assays. In this review, we summarize the current status and limitations of PD-L1 testing for patients with NSCLC in China and discuss recent progress in artificial intelligence-assisted PD-L1 scoring. Our review aims to support improvements in clinical PD-L1 testing practice and optimization of the prognosis and outcomes of immunotherapy in this patient population.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973252 | PMC |
| http://dx.doi.org/10.1111/1759-7714.70042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: In Armenia, a lower-middle-income country, cancer causes 21% of all deaths, with over half of cases diagnosed at advanced stages. Without universal health insurance, patients rely on out-of-pocket payments or black-market channels for costly immunotherapies, underscoring the need for real-world data to inform equitable policy reforms.
Methods: We conducted a multicenter, retrospective cohort study of patients who received at least one dose of an immune checkpoint inhibitor (ICI) between January 2017 and December 2023 across six Armenian oncology centers.
PD-L1 expression in locally advanced cervical cancer: A pilot cross clone comparison study.
Int J Radiat Oncol Biol Phys
September 2025
Department of Radiation Oncology, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India. Electronic address:
Purpose: Recent immunotherapy trials in locally advanced cervical cancer report high PD-L1 positivity rates whereas academic multicentric initiatives report a lower PD-L1 positivity. These observations necessitate cross-clone comparison to understand the observed differences.
Methods: Two different clones used in previous multicentric international studies SP142 (BIOEMBRACE) and 22C3 (KEYNOTE-A18) were used to test PD-L1 positivity in a pilot cohort of FIGO 2018 stage III cervical cancer patients recruited in a phase III trial.
Implementing a PREcision meDICine Thoracic (PREDICT) service using in-house reflex testing in a large academic-community practice.
Chest
September 2025
Case Western Reserve University, Cleveland, OH; University Hospitals, Cleveland, OH.
Background: Broad genomic testing is necessary to treat stage IV non-small cell lung cancer (NSCLC) patients. We describe a NSCLC precision medicine service at an academic-community practice and provide model-based estimates of the impact of a similar intervention.
Research Question: Will implementation of a precision medicine service increase NSCLC next-generation sequencing (NGS) rates, improve testing turnaround times (TAT), and increase rates of actionable genomic alterations (AGAs)?
Study Design And Methods: PREDICT (PREcision meDICine Thoracic) consisted of: 1) system-wide reflex testing of stage IV NSCLC patients by in-house solid tumor NGS focused assay and PD-L1 testing, 2) navigator, 3) molecular tumor board (MTB), 4) integrated information portal (OncoTracker) for real-time updates on samples processing, results, and treatment recommendations by the MTB.
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap.
Immunotherapy
August 2025
Department of Medical Oncology, Fortrea Inc., Durham, NC, USA.
Introduction: Pembrolizumab is a standard first-line therapy for advanced/metastatic non-small cell lung cancer (a/mNSCLC) lacking actionable mutations. Data from lower-middle-income countries (LMICs) remain scarce.
Methods: From January 2019 to June 2024, we prospectively analyzed 78 a/mNSCLC patients receiving pembrolizumab-based first-line therapy.
Diagnostic Evaluation of Anaplastic Thyroid Carcinoma in Core Biopsy Specimens: Morphologic, Immunohistochemical, Molecular, and Therapeutic Considerations.
Endocr Pathol
September 2025
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Although a diagnosis of anaplastic thyroid carcinoma (ATC) can be rendered on fine needle aspiration (FNA), a core needle biopsy is often performed to provide sufficient material for immunohistochemical and molecular analysis. Rendering an ATC diagnosis on core biopsy can be challenging due to limited material. It is crucial that other diagnostic entities in the differential, such as poorly differentiated thyroid carcinoma, medullary thyroid carcinoma, lymphoma, metastases, and NUT carcinoma (among others), are considered and that immunohistochemistry (IHC) is employed judiciously to support the diagnosis.
View Article and Find Full Text PDF